<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01669499</url>
  </required_header>
  <id_info>
    <org_study_id>ZonMW 11510009</org_study_id>
    <nct_id>NCT01669499</nct_id>
  </id_info>
  <brief_title>Dexamethasone for Pain Flare After Radiotherapy of Painful Bone metastasesZonMW 11510009</brief_title>
  <official_title>Dexamethasone for the Prevention of a Pain Flare After Palliative Radiotherapy for Painful Bone Metastases: a Multi-center Double-blind Placebo-controlled Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer patients with pain due to bone metastases are often treated with external irradiation&#xD;
      in order to reduce pain. However, patients may experience a temporary increase of pain&#xD;
      shortly after irradiation, a so-called pain flare. This study investigates whether a short&#xD;
      course of a drug called dexamethasone may prevent the occurrence of a pain flare. Patients,&#xD;
      who are irradiated for painful bone metastases are randomized into three groups. Group 1&#xD;
      receives placebo during four days, group 2 receives dexamethasone on the day of the&#xD;
      irradiation and placebo during three days, and group 3 receives dexamethasone during four&#xD;
      days. All patients complete a questionnaire on pain, side-effects of treatment and quality of&#xD;
      life during 14 days and after four weeks. This study will define whether dexamethasone&#xD;
      decreases the occurrence of a pain flare after irradiation for painful bone metastases, and,&#xD;
      if so, whether four days of treatment with dexamethasone is better dan one day of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background of the study:&#xD;
&#xD;
      Patients with pain due to bone metastases are often treated with palliative short schedule&#xD;
      external beam radiotherapy. Dependent on the institutional protocols, single fraction (8 Gy)&#xD;
      or 5-6 fractions of 4 Gy are usually applied. Randomized studies have shown the equal&#xD;
      effectiveness of both schedules in treating pain, with almost 70% of patients experiencing&#xD;
      less or no pain within three to four weeks after treatment (Wu 2003). However, within 10 days&#xD;
      after treatment a short term transient progression of pain may occur, the so-called pain&#xD;
      flare (Chow 2005, Loblaw 2007, Hird 2009-1). Two prospective observational studies reported&#xD;
      patient-based daily pain scores after radiotherapy for painful bone metastases. Loblaw showed&#xD;
      a pain flare in 44% patients after 8 Gy and in 24% patients after 20 Gy in 4 fractions&#xD;
      (Loblaw 2007). The median duration of the pain flare was three days. A recent publication&#xD;
      found no difference in pain flare in 111 patients after single vs. multiple fractions (39%&#xD;
      vs. 41%, resp.) (Hird 2009-1). No data are available of the occurrence of pain flare in Dutch&#xD;
      patients. The largest trial to date on painful bone metastases, the Dutch Bone Metastasis&#xD;
      Study, was funded by OG and CKTO and randomized from 1996-1998 a total of 1157 patients&#xD;
      between 8 Gy single fraction and 24 Gy in 6 fractions (PhD thesis, van der Linden 2005).&#xD;
      Follow-up consisted of 12 weekly and thereafter monthly questionnaires on pain, pain&#xD;
      medication and quality of life. In this study, daily scoring of pain to asses pain flare was&#xD;
      not performed. When a pain flare occurs oral dexamethasone can be prescribed. The rationale&#xD;
      for administering steroids is to decrease edema that arises in the periostium of the affected&#xD;
      bone shortly after radiotherapy and thereby to reduce pain (de Graeff 2006). Two small&#xD;
      studies were performed to study the effectiveness of dexamethasone for treating a pain flare&#xD;
      (Chow 2007, Hird 2009-2). Chow et al. administered 8 mg dexamethasone to 23 patients one hour&#xD;
      before single fraction treatment and showed pain flare in only 24% of patients (95% CI&#xD;
      10-39%) within the first 10 days after radiotherapy (Chow 2007). Only one patient had a flare&#xD;
      within two days after treatment. Dexamethasone was well tolerated. In a fase 2 study of the&#xD;
      same research group 41 patients were administered 8 mg dexamethasone before and then for&#xD;
      three consecutive days after single fraction treatment. They showed a pain flare in 22% of&#xD;
      patients (with a median duration of one day), with 81% occurring within five days after&#xD;
      treatment, and 95% within 10 days (Hird 2009-2). Both studies concluded that randomized&#xD;
      studies are necessary to collect unbiased data on the occurrence and duration of pain flare&#xD;
      and the effectiveness of drug treatment. Until now, no randomized studies were performed&#xD;
      comparing dexamethasone with placebo or no treatment. The effectiveness of placebo vs.&#xD;
      dexamethasone in the treatment of pain flare in patients after radiotherapy for painful bone&#xD;
      metastases is the subject of this study.&#xD;
&#xD;
      Aim of the study To study the effectiveness and toxicity of dexamethasone to prevent the&#xD;
      occurrence of a pain flare after short schedule radiotherapy for painful bone metastases and&#xD;
      to define the optimal schedule of dosing.&#xD;
&#xD;
      Research questions:&#xD;
&#xD;
        1. What is the effectiveness of dexamethasone to prevent the occurrence of a pain flare&#xD;
           after short schedule radiotherapy for painful bone metastases?&#xD;
&#xD;
        2. Is there a difference in effectiveness between a single dose of 8 mg dexamethasone&#xD;
           before radiotherapy or a dose of 8 mg dexamethasone before radiotherapy in combination&#xD;
           with three additional doses during the three following days?&#xD;
&#xD;
        3. What are the side effects of dexamethasone and placebo in patients treated with&#xD;
           radiotherapy for painful bone metastases? 4. Does a pain flare predict for pain response&#xD;
           to radiotherapy?&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      This study is a randomized, controlled, multicenter study in 411 patients with painful bone&#xD;
      metastases who are referred for a short course of palliative radiotherapy. Short course&#xD;
      radiotherapy encompasses all treatment schedules from one to six fractions of radiotherapy.&#xD;
      The study consists of three arms:&#xD;
&#xD;
        -  Arm 1: day 0: placebo, day 1, 2 en 3: placebo&#xD;
&#xD;
        -  Arm 2: day 0: 8 mg dexamethasone, day 1, 2 en 3: placebo&#xD;
&#xD;
        -  Arm 3: day 0: 8 mg dexamethasone, day 1, 2 en 3: 8 mg dexamethasone Day 0 is the first&#xD;
           day of radiotherapy treatment. On day 0 the tablet of placebo or dexamethasone will be&#xD;
           administered one hour before radiotherapy. On day 1, 2, and 3 the tablet of placebo or&#xD;
           dexamethasone will be taken in the morning at about 8 a.m.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The occurrence of a pain flare.</measure>
    <time_frame>Within 2 weeks after irradiation</time_frame>
    <description>A pain flare is defined by a two-point increase after radiotherapy of the worst pain score on Pain flare is defined as an 11-point scale of 0 (no pain) to 10 (worst imaginable pain) compared to baseline without a decrease in analgesic intake, or a 25% increase in analgesic intake without decrease in worst pain score (according to international bone metastases consensus guidelines) (Chow 2007).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain scores</measure>
    <time_frame>Days 1-14 and 28</time_frame>
    <description>Pain scores as measured by BPI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Days 7, 14 and 28</time_frame>
    <description>As measured by the quality of life scale of the EORTC PAL15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>Day 1-14</time_frame>
    <description>As measured by questionnaire</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">411</enrollment>
  <condition>Bone Metastases</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo on day 0-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone acetate day 0</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 mg dexamethasone on day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone acetate day 0-3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 mg dexamethasone on day 0-3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone acetate</intervention_name>
    <arm_group_label>Dexamethasone acetate day 0</arm_group_label>
    <arm_group_label>Dexamethasone acetate day 0-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Dexamethasone acetate day 0</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of 18 years or older&#xD;
&#xD;
          -  Uncomplicated painful bone metastases&#xD;
&#xD;
          -  Primary malignancy is a solid tumour â€¢ Pain intensity on a numeric rating scale of 2-8&#xD;
&#xD;
          -  No immediately expected change in the analgesic regimen.&#xD;
&#xD;
          -  Indication for single or short course radiotherapy&#xD;
&#xD;
          -  Able to fill out Dutch questionnaires&#xD;
&#xD;
          -  Able to follow instructions&#xD;
&#xD;
          -  Informed consent provided&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with hematological malignancy&#xD;
&#xD;
          -  Multliple sites to be irradiated&#xD;
&#xD;
          -  Patients who have been treated before with palliative radiotherapy for painful bone&#xD;
             metastases&#xD;
&#xD;
          -  Current use of steroids (dexamethasone, prednisolone or other), or use up to less than&#xD;
             a week before randomization&#xD;
&#xD;
          -  Long-term schedule radiotherapy (&gt;6 fractions)&#xD;
&#xD;
          -  Life expectancy shorter than 8 weeks&#xD;
&#xD;
          -  Karnofsky Performance Score of 40 or less&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander de Graeff, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Oncologist</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leiden University Medical Centre</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3485 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>August 16, 2012</study_first_submitted>
  <study_first_submitted_qc>August 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2012</study_first_posted>
  <last_update_submitted>November 15, 2016</last_update_submitted>
  <last_update_submitted_qc>November 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>A. de Graeff</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Bone metastases, radiotherapy, dexamethasone, pain flare</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

